ReviewFrontiers in cell and developmental biology2025
Pharmacologically targeting Schwann cells to improve regeneration following nerve damage.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Regenerative strategies for ALS: stem cells and extracellular vesicles.Discover nano · 2026Review
- Wallerian Degeneration and Nerve Regeneration-A Review of Cellular and Molecular Events.International journal of molecular sciences · 2026Review
- Comparison of serum vitamin D level and vitamin D receptor gene FokI polymorphism in leprosy patients with and without trophic ulcers: A case-control study.PLoS neglected tropical diseases · 2026Article
- Contemporary Strategies of Gene and Cell Therapy in the Treatment of Peripheral Nervous System Injuries and Disorders.International journal of molecular sciences · 2026Review
- Neuromuscular Junction as a Molecular Target in Sarcopenia: Mechanisms, Therapeutic Strategies, and Future Directions.Molecular diagnosis & therapy · 2026Review
- Histological and Immunohistochemical Characterization of the Tibial ACL Remnant: Implications for Ligament Healing.Medicina (Kaunas, Lithuania) · 2026Article
- Paeoniflorin as a candidate disease-modifying therapy for diabetic peripheral neuropathy: mechanisms, exposure challenges, and translational priorities.Frontiers in pharmacology · 2026Review
- Neuroinflammation-Modulating Properties Combining Glutathione, N-Acetylcysteine, and Uridine Monophosphate in a Formulation Supplement: An In Vitro Study.Brain sciences · 2025Article
- A Novel Hydrogel for Treatment and Prevention of Symptomatic Neuroma: Early Clinical Experience.Plastic and reconstructive surgery. Global open · 2025Article
- Developmental switch in immunolocalization of phosphodiesterase 7A protein in testicular cells of mice, rats, and camels.Open veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schwann cells provide essential support for nerve growth and survival following peripheral nerve damage by producing various growth factors and other signalling molecules. Modulating the proliferation, differentiation, migration, or myelination of Schwann cells could result in accelerated repair and regeneration of injured nerves, ultimately leading to improved motor and sensory function. Therefore, Schwann cells are commonly advocated as therapeutic targets for nerve damage, which could be mediated by pharmacological intervention. This review discusses how compounds such as growth factors, hormones, and small molecules can regulate intracellular signalling pathways involved in modulating Schwann cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.